Targeted Therapy in Head and Neck Cancer

Forastiere A. , Koch W. , Trotti A. , Sidransky D. : Medical progress-head and neck cancer. N Engl J Med, 345: 1890–1900, 2001.

Mimeault M. , Hauke R. , Mehta P.P. , Batra S.K. : Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med, 11: 981–1011, 2007.

Bianchini C. , Ciorba A. , Pelucchi S. , Piva R. , Pastore A. : Head and neck cancer: the possible role of stem cells. Eur Arch Otorhinolaryngol, 265: 17–20, 2008.

Graziano A. , d'Aquino R. , Tirino V. , Desiderio V. , Rossi A. , Pirozzi G. : The stem cell hypothesis in head and neck cancer. J Cell Biochem, 103: 408–412, 2008.

Prince M.E. , Ailles L.E. : Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol, 26: 2871–2875, 2008.

Braakhuis B.J. , Leemans C.R. , BrakenhoV R.H. : Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol, 15: 113–120, 2005.

Hirata Y. : Progression of cancer. Med Hypotheses, 52: 51–113, 1999.

Gollin S.M. : Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck, 23: 238–253, 2001.

Dietz A. , Boehm A. , Mozet C. , Wichmann G. , Giannis A. : Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol, 265 Suppl: S3–12, 2008.

Mimeault M. , Batra S.K. : Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells, 24: 2319–2345, 2006.

Mimeault M. , Hauke R. , Batra S.K. : Recent advances on the molecular mechanisms involved in drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther, 82: 252–264, 2007.

Dean M. , Fojo T. , Bates S. : Tumour stem cells and drug resistance. Nat Rev Cancer, 5: 275–284, 2005.

Barker N. , Clevers H. : Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov, 5: 997–1014, 2006.

Rubin L.L. , de Sauvage F.J. : Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov, 5: 1026–1033, 2006.

Roberg K. , Jonsson A.C. , Grenman R. , Norberg-Spaak L. : Radiotherapy response in oral squamous carcinoma cell lines: evaluation of apoptotic proteins as prognostic factors. Head Neck, 29: 325–334, 2007.

Mimeault M. , Batra S. : Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol, 18: 1605–1619, 2007.

Mimeault M. , Batra S.K. : Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev, 26: 203–214, 2007.

Fodde R. , Brabletz T. : Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol, 19: 150–158, 2007.

Zhang Q. , Chen G. , Liu X. , Qian Q. : Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res, 17: 89–99, 2007.

Goerner M. , Seiwert T.Y. , Sudhoff H. : Molecular targeted therapies in head and neck cancer - An update of recent developements. Head Neck Oncol, 2: 8–10, 2010.

Razak A.R. , Siu L.L. , Le Tourneau C. : Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol, 22: 212–220, 2010.

Le Tourneau C. , Siu L.L. : Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Current Opinion in Oncology, 20: 256–263, 2008.

Vermorken J.B. , Trigo J. , Hitt R. , Koralewski P. , Diaz-Rubio E. , Rolland F. , Knecht R. , Amellal N. , Schueler A. , Baselga J. : Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 25: 2171–2177, 2007.

Kirby A.M. , A'Hern R.P. , D'Ambrosio C. , Tanay M. , Syrigos K.N. , Rogers S.J. , Box C. , Eccles S.A. , Nutting C.M. , Harrington K.J. : Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer, 94: 631–636, 2006.

Stewart J.S.W. , Cohen E.E.W. , Licitra L. : A phase III randomized parallel group study of gefitinib (RESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck [abstract]. In: American Association for Cancer Research Annual Meeting: Proceedings; 14–18 Apr 2007; Los Angeles, Philadelphia: AACR; 2007, Abstract 3522.

Baselga J. , Trigo J.M. , Bourhis J. , Tortochaux J. , Cortés-Funes H. , Hitt R. , Gascón P. , Amellal N. , Harstrick A. , Eckardt A. : Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol, 23: 5568–5577, 2005.

Herbst R.S. , Arquette M. , Shin D.M. , Dicke K. , Vokes E.E. , Azarnia N. , Hong W.K. , Kies M.S. : Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol, 23: 5578–5587, 2005.

Burtness B. , Goldwasser M.A. , Flood W. , Mattar B. , Forastiere A.A. : Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic / recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol, 23: 8646–8654, 2005.

Siu L.L. , Soulieres D. , Chen E.X. , Pond G.R. , Chin S.F. , Francis P. , Harvey L. , Klein M. , Zhang W. , Dancey J. , Eisenhauer E.A. , Winquist E. : Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol, 25: 2178–2183, 2007.

Cohen E.E. , Davis D.W. , Karrison T.G. , Seiwert T.Y. , Wong S.J. , Nattam S. , Kozloff M.F. , Clark J.I. , Yan D.H. , Liu W. , Pierce C. , Dancey J.E. , Stenson K. , Blair E. , Dekker A. , Vokes E.E. : Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol, 10: 247–257, 2009.

Matta A. , Ralhan R. : Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol, 1: 6–10, 2009.

Slaughter D.P. , Southwick H.W. , Smejkal W. : “Field cancerization” in oral stratified squamous epithelium. Cancer, 6: 963–968, 1953.

Leemans C.R. , Tiwari R. , Nauta J.J. , van der Waal I. , Snow G.B. : Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer, 73: 187–190, 1994.

Braakhuis B.J. , Brakenhoff R.H. , Leemans C.R. : Gene expression profiling in head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg, 18: 67–71, 2010.

Ha P.K. , Califano J.A. : The Molecular Biology of Mucosal Field Cancerization of the Head and Neck. Critical Reviews in Oral Biology & Medicine, 14: 363–369, 2003.

Mahfouz M.E. , Rodrigo J.P. , Takes R.P. , Elsheikh M.N. , Rinaldo A. , Brakenhoff R.H. , Ferlito A. : Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol, 267: 851–860, 2010.

Langer C.J. : Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer, 112: 2635–2645, 2008.

Mimeault M. , Batra S.K. : Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev, 8: 94–112, 2009.

Szakács G. , Paterson J.K. , Ludwig J.A. , Booth-Genthe C. , Gottesman M.M. : Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5: 219–234, 2006.

Kim S. , Grandis J.R. , Rinaldo A. , Takes R.P. , Ferlito A. : Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck, 30: 667–674, 2008.

Barnes C.J. , Ohshiro K. , Rayala S.K. , El-Naggar A.K. , Kumar R. : Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res, 13: 4291–4299, 2007.

Hong D.Y. , Lee B.J. , Lee J.C. , Choi J.S. , Wang S.G. , Ro J.H. : Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma. Clin Exp Otorhinolaryngol, 2: 186–192, 2009.

Wang X. , Hao M.W. , Dong K. , Lin F. , Ren J.H. , Zhang H.Z. : Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res, 32: 1263–1269, 2009.

Kurihara Y. , Watanabe Y. , Onimatsu H. , Kojima T. , Shirota T. , Hatori M. , Liu D. , Kyo S. , Mizuguchi H. , Urata Y. , Shintani S. , Fujiwara T. : Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res, 15: 2335–2343, 2009.

Rubin Grandis J. , Melhem M.F. , Gooding W.E. , Day R. , Holst V.A. , Wagener M.M. , Drenning S.D. , Tweardy D.J. : Levels of TGF alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst, 90: 824–832, 1998.

Grandis J.R. , Chakraborty A. , Zeng Q. , Melhem M.F. , Tweardy D.J. : Down modulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem, 69: 55–62, 1998.

Lin D.T. , Subbaramaiah K. , Shah J.P. , Dannenberg A.J. , Boyle J.O. : Cyclooxygenase-2: a novel molecular target for the prevention, treatment of head, neck cancer. Head Neck, 24: 792–799, 2002.